Updated:
Rapport Therapeutics
Rapport Therapeutics launched in March 2023, backed by founding investor Third Rock Ventures alongside ARCH Venture Partners and Johnson & Johnson...
Rapport Therapeutics
Rapport Therapeutics launched in March 2023, backed by founding investor Third Rock Ventures alongside ARCH Venture Partners and Johnson & Johnson Innovation. The neuroscience company was built around the scientific discoveries of David Bredt, its chief scientific officer, who previously led neuroscience discovery at Janssen and co-discovered receptor-associated proteins. This academic-to-industry lineage shapes the firm's identity: a platform company translating deep biology into precisely targeted brain therapies. The firm's strategy focuses on developing small-molecule precision medicines for central nervous system disorders. Rather than traditional neurotransmitter-based approaches, Rapport targets receptor-associated proteins — structural scaffolds that organize receptors into micro-domains — to achieve regional specificity in the brain. Its lead program, RAP-219, is designed as a next-generation AMPA receptor modulator for drug-resistant epilepsy. The pipeline also includes preclinical ion channel targets for chronic pain and bipolar disorder. The company deploys capital through centralized R&D operations in Boston, with clinical development activities spanning North American trial sites. Rapport emerged from stealth in 2023 with $100 million in Series A financing, a capital-intensive model typical of platform biotechs that internalize discovery through clinical proof-of-concept. In August 2023, the firm expanded its leadership, appointing industry veteran Trung Nguyen as chief operating officer to scale operations. The company operates from a single headquarters in Boston's Seaport district, maintaining a lean, science-driven organization that relies on external CRO networks for clinical execution. No philanthropic or adjacent vehicles have been disclosed. The firm's structural differentiator lies in its receptor-associated protein platform, which provides a proprietary biological lens to discover drugs that target specific brain circuits without systemic side effects. This horizontal platform model — where one mechanism yields multiple pipeline programs — mirrors the architecture of earlier Third Rock successes like Editas Medicine and Relay Therapeutics, positioning Rapport as an IP-generation engine rather than a single-asset biotech.
General information
Firm type
Asset Manager
Year founded
2020
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Principals
David Bredt
Chief Scientific Officer
Sector focus
Frequently asked questions
What is Rapport Therapeutics' core scientific platform?
Rapport targets receptor-associated proteins (RAPs), which act as structural scaffolds organizing neurotransmitter receptors into specific micro-domains within neurons. This approach allows the company to develop drugs that modulate brain circuit activity with regional precision, avoiding the widespread side effects common in traditional CNS medications. The platform emerged from research co-authored by CSO David Bredt during his tenure at Janssen.
How does Rapport Therapeutics fit within the Third Rock Ventures portfolio?
Third Rock incubated Rapport in stealth for roughly three years before leading its $100 million Series A alongside ARCH and J&J Innovation. This follows Third Rock's model of building platform biotechs around a founding scientific insight, as seen with Editas and Relay Therapeutics. The firm typically provides operational support during the early clinical phase, which Rapport entered in 2023.
What is Rapport's lead drug candidate and what disease does it target?
The lead program is RAP-219, a novel AMPA receptor modulator in development for drug-resistant focal epilepsy. By targeting RAPs that localize AMPA receptors along specific neuronal pathways, RAP-219 aims to reduce seizure activity without the cognitive dulling or sedation associated with current epilepsy drugs. Preclinical data supporting regional specificity was published prior to the company's public launch.
Who are the key scientific founders and how did they build the company prior to Series A?
David Bredt, a neuroscientist who previously led global neuroscience discovery at Janssen, serves as CSO and is the central scientific founder. He and his academic collaborators identified RAPs as druggable targets. Third Rock Ventures formed Rapport around this IP circa 2020 and funded operations before the 2023 public launch, during which time Bredt assembled a team to advance multiple ion channel programs.
What neurological indications beyond epilepsy is Rapport targeting?
Beyond RAP-219 for epilepsy, Rapport has disclosed an early-stage ion channel program for chronic pain and a program in bipolar disorder. Both leverage the RAP platform to design subtype-selective modulators. As of 2023, the firm described these as preclinical, and specific ion channel targets had not been publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: